---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-26-000988"
form_type: "8-K"
ticker: "AVXL"
cik: "0001314052"
company_name: "ANAVEX LIFE SCIENCES CORP."
filed_at: "2026-07-30T12:15:52+00:00"
generated_at: "2026-07-30T12:20:11.075209+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Anavex reports preliminary Q2 FY2026 net loss of $5.3M; cash $127.4M; focuses on FDA for Alzheimer's

## Summary
- Preliminary net loss $5.3M ($0.06/share) vs $11.2M ($0.13/share) in Q2 2025; R&D expenses down to $4.2M from $9.9M.
- Cash and equivalents $127.4M as of March 31, 2026, up from $102.6M at Sept 30, 2025; expected to fund operations into mid-to-late FY2028.
- Opened IND for early Alzheimer's disease with FDA in March 2026; ADME study expected Q3 2026, DDI study underway.
- Aligned with FDA on Phase 3 Rett syndrome protocol for adults; plans to discuss adding pediatric patients.
- Submitted plan to regain Nasdaq compliance on July 20, 2026 (Listing Rule 5250(c)(1)).

## SEC filing metadata
- accession: 0001731122-26-000988
- form_type: 8-K
- ticker: AVXL
- cik: 0001314052
- company_name: ANAVEX LIFE SCIENCES CORP.
- filed_at: 2026-07-30T12:15:52+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314052/000173112226000988/0001731122-26-000988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314052/000173112226000988/e7813_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-26-000988
- JSON: https://secwatch.observer/filing/0001731122-26-000988.json
- Plain text: https://secwatch.observer/filing/0001731122-26-000988.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.